Triazole antifungal agents in invasive fungal infections: A comparative review

Drugs

Volumn 71, Issue 18, 2011, Pages 2405-2419

  Lass Flörl, Cornelia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Drug monitoring; Fluconazole; Itraconazole; Mycoses; Posaconazole; Triazoles; Voriconazole

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CYCLODEXTRIN; CYTOCHROME P450; ECHINOCANDIN; EFAVIRENZ; FLUCONAZOLE; HYDROXYITRACONAZOLE; ITRACONAZOLE; METOCLOPRAMIDE; MICAFUNGIN; PHENYTOIN; POSACONAZOLE; RIFABUTIN; URIDINE DIPHOSPHATE; VORICONAZOLE;

ASPERGILLOSIS; BLASTOMYCOSIS; CANDIDEMIA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CLINICAL TRIAL (TOPIC); COCCIDIOIDOMYCOSIS; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DERMATOMYCOSIS; DIARRHEA; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CONCENTRATION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FUSARIOSIS; GLUCURONIDATION; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HISTOPLASMOSIS; HUMAN; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; INVASIVE ASPERGILLOSIS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIPID DIET; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LOADING DRUG DOSE; MENTAL DISEASE; META ANALYSIS (TOPIC); MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NAIL INFECTION; NAUSEA; NEUTROPENIA; OROPHARYNX CANDIDIASIS; PSEUDALLESCHERIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SALVAGE THERAPY; SINGLE DRUG DOSE; STOMACH PH; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VISUAL DISORDER; VOMITING;

EID: 82955169573     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11596540-000000000-00000     Document Type: Review

References (110)

1. Vfend [package insert]. New York: Pfizer Inc., 2010
2. Sporanox oral solution [package insert]. Raritan (NJ): Orth Biotech Products, L.P., 2003
3. Noxafil [package insert]. Kenilworth (NJ): Schering-Plough, 2009
4. Diflucan [package insert]. New York: Pfizer Inc., 2010
5. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-52
6. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 1325-30 (Pubitemid 24347001)
7. Glasmacher A, Cornely O, Ullmann AJ, et al. An openlabel randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006; 57: 317-25 (Pubitemid 43160176)
8. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4615-26 (Pubitemid 46594036)
9. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-33 (Pubitemid 38168674)
10. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13
11. Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol 2003; 109: 111-8 (Pubitemid 36506370)
12. Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33: e83-90
13. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive Aspergillosis. Am JMed 1994; 97: 135-44 (Pubitemid 24250673)
14. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990; 23: 607-14 (Pubitemid 20263688)
15. Denning DW, Riniotis K, Dobrashian R, et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37 Suppl. 3: S265-80 (Pubitemid 37260464)
16. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342: 756-62 (Pubitemid 30151919)
17. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in nonneutropenic patients: a randomised noninferiority trial. Lancet 2005; 366: 1435-42 (Pubitemid 41483809)
18. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15 (Pubitemid 34851833)
19. Schwartz S, RuhnkeM,Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-5 (Pubitemid 41510735)
20. Mouas H, Lutsar I, Dupont B, et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 2005; 40: 1141-7 (Pubitemid 40490239)
21. Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 2006; 52: e133-7
22. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47 (Pubitemid 46148776)
23. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59 (Pubitemid 46148777)
24. Mohr J, Johnson M, Cooper T, et al. Current options in antifungal pharmacotherapy. Pharmacotherapy 2008; 28: 614-45 (Pubitemid 351620030)
25. Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003; 17: 159-91 (Pubitemid 36514575)
26. Warrilow AG, Martel CM, Parker JE, et al. Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother 2010; 54: 4235-45
27. Lass-Flö rl C, Mayr A, Perkhofer S, et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2008; 52: 3637-41
28. Van de Velde VJ, Van Peer AP, Heykants JJ, et al. Effect of food on the pharmacokinetics of a new hydroxypropylbeta-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996; 16: 424-8
29. Lass-Flö rl C. The changing face of epidemiology of invasive fungal diseases in Europe. Mycoses 2009; 52 (3): 197-205
30. Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 2010; 18: 195-204
31. Lipp HP. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br J Clin Pharmacol 2010; 70: 471-80
32. Li Y, Theuretzbacher U, Clancy CJ, et al. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet 2010; 49: 379-96
33. Purkins L, Wood N, Kleinermans D, et al. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003; 56 Suppl. 1: 17-23 (Pubitemid 37491729)
34. Andes D. Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Curr Opin Infect Dis 2004; 17: 533-40 (Pubitemid 39627514)
35. Purkins L, Wood N, Kleinermans D, et al. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003; 56 Suppl. 1: 51-5 (Pubitemid 37491734)
36. Zimmermann T, Yeates RA, Laufen H, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994; 46: 147-50 (Pubitemid 24101333)
37. Zimmermann T, Yeates RA, Riedel KD, et al. The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. Int J Clin Pharmacol Ther 1994; 32: 491-6 (Pubitemid 24277060)
38. Sporanox capsules [package insert]. Raritan (NJ): PriCara, 2009
39. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37: 778-84 (Pubitemid 23096878)
40. Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36: 423-6 (Pubitemid 19140050)
41. Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44: 211-20 (Pubitemid 40188942)
42. Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004; 48: 804-8 (Pubitemid 38280328)
43. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57: 218-22 (Pubitemid 38223535)
44. Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 958-66
45. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006; 50: 1881-3
46. Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 2010; 30: 842-54
47. Arndt CA, Walsh TJ, McCully CL, et al. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988; 157: 178-80 (Pubitemid 18037468)
48. Foulds G, Brennan DR, Wajszczuk C, et al. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 1988; 28: 363-6 (Pubitemid 19013387)
49. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37: 728-32 (Pubitemid 37100817)
50. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53: 24-34
51. Nivoix Y, Ubeaud-Sequier G, Engel P, et al. Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab 2009; 10: 395-409
52. Hafner V, Czock D, Burhenne J, et al. Pharmacokinetics of sulfobutyletherbeta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother 2010; 54: 2596-602
53. Keating GM. Posaconazole. Drugs 2005; 65 (11): 1553-67; discussion 1568-9 (Pubitemid 41124308)
54. Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21: 645-53 (Pubitemid 38447146)
55. Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004; 48: 3543-51 (Pubitemid 39129357)
56. Andes D, Marchillo K, Conklin R, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004; 48: 137-42 (Pubitemid 38040189)
57. Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165-9 (Pubitemid 37229574)
58. Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 1193-9 (Pubitemid 36368574)
59. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999; 43: 2116-20 (Pubitemid 29421186)
60. Louie A,Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998; 42: 1105-9 (Pubitemid 28227905)
61. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006; 20: 679-97 (Pubitemid 44375115)
62. Mavridou E, Bruggemann RJ, Melchers WJ, et al. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 2010; 54: 4758-64
63. Mavridou E, Bruggemann RJ, MelchersWJ, et al. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 2010; 54: 860-5
64. Eiden C, Peyriere H, Tichit R, et al. Inherited long QT syndrome revealed by antifungals drug-drug interaction. J Clin Pharm Ther 2007; 32: 321-4 (Pubitemid 46699512)
65. Esch JJ, Kantoch MJ. Torsades de Pointes ventricular tachycardia in a pediatric patient treated with fluconazole. Pediatr Cardiol 2008; 29: 210-3
66. Justo D, Zeltser D. Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports. Mycoses 2006; 49: 463-70 (Pubitemid 44511096)
67. Owens Jr RC, Nolin TD. Antimicrobial-associated QT interval prolongation: points of interest. Clin Infect Dis 2006; 43: 1603-11 (Pubitemid 44910994)
68. Pham CP, de Feiter PW, van der Kuy PH, et al. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother 2006; 40: 1456-61 (Pubitemid 44204980)
69. Prosser JM, Mills A, Rhim ES, et al. Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus. Int J Emerg Med 2008; 1: 217-20
70. Tatetsu H, AsouN, NakamuraM, et al. Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia. Am J Hematol 2006; 81: 366-9
71. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58 (Pubitemid 35168437)
72. Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009; 68: 906-15
73. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532-5 (Pubitemid 46595688)
74. Matsumoto K, Ikawa K, Abematsu K, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009; 34: 91-4
75. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11 (Pubitemid 351269158)
76. Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010; 50: 27-36
77. Pascual A, Nieth V, Calandra T, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and biomass methods. Antimicrob Agents Chemother 2007; 51: 137-43 (Pubitemid 46047698)
78. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570-2
79. Imhof A, Schaer DJ, Schanz U, et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006; 136: 739-42 (Pubitemid 46032197)
80. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71 (Pubitemid 34165316)
81. Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46: 235-43 (Pubitemid 43146453)
82. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509-13 (Pubitemid 40403355)
83. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658-66 (Pubitemid 43190980)
84. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006; 50: 1993-9 (Pubitemid 43807517)
85. Kohl V, Muller C, Cornely A, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 2010; 54: 207-12
86. Krishna G, Parsons A, Kantesaria B, et al. Evaluation of the pharmacokinetics of posaconazole and rifabutin following coadministration to healthy men. Curr Med Res Opin 2007; 23: 545-52 (Pubitemid 46456902)
87. Jain R, Pottinger P. The effect of gastric acid on the absorption of posaconazole [letter]. Clin Infect Dis 2008; 46 (10): 1627; author reply 1627-8 (Pubitemid 351706748)
88. Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88: 115-9
89. Mayr A, Lass-Flö rl C. Epidemiology and antifungal resistance in invasiveAspergillosis according to primary disease: review of the literature. Eur J Med Res 2011; 16: 153-7
90. Binder U, Lass-Flö rl C. Epidemiology of invasive fungal infections in the mediterranean area. Mediterr J Hematol Infect Dis. Epub 2011 Mar 31
91. Lewis RE. Antifungal drug monitoring. Curr Fungal Infect Rep 2010; 4: 158-67
92. Hope WW, Billaud EM, Lestner J, et al. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008; 21: 580-6
93. Perkhofer S, Lass-Flö rl C, Hell M, et al. The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents 2010; 36: 531-6
94. Gafter-Gvili A, Vidal L, Goldberg E, et al. Treatment of invasive candidal infections: systematic review and metaanalysis. Mayo Clin Proc 2008; 83: 1011-21
95. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, et al. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22: 651-5 (Pubitemid 37491617)
96. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-31 (Pubitemid 36549632)
97. Steinbach WJ, Benjamin Jr DK, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-8 (Pubitemid 38971489)
98. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled blinded trial. Clin Infect Dis 2007; 44: 2-12 (Pubitemid 44968977)
99. Mukherjee PK, Sheehan DJ, Hitchcock CA, et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005; 18: 163-94 (Pubitemid 40170667)
100. Lyseng-Williamson KA. Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts. Pharmacoeconomics 2011 Mar 1; 29 (3): 251-68
101. Jansen JP, O'Sullivan AK, Lugtenburg E, et al. Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. Ann Hematol 2010; 89: 919-26
102. Stam WB, O'Sullivan AK, Rijnders B, et al. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 2008; 81: 467-74
103. Greiner RA, Meier Y, Papadopoulos G, et al. Costeffectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland. Oncology 2010; 78: 172-80
104. Dranitsaris G, Khoury H. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasis: a cost effectiveness analysis. Support Care Cancer 2010; 19 (11): 1807-13
105. Al-Badriyeh D, Liew D, Stewart K, et al. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. J Antimicrob Chemother 2009; 63: 197-208
106. Al-Badriyeh D, Heng SC, Neoh CF, et al. Pharmacoeconomics of voriconazole in the management of invasive fungal infections. Expert Rev Pharmacoecon Outcomes Res 2010; 10: 623-36
107. Sohn HS, Lee TJ, Kim J, et al. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Clin Ther 2009; 31: 1105-15
108. Pechlivanoglou P, Vries RD, Daenen SM, et al. Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence. Pharmacoeconomics 2011; 29 (9): 737-51
109. Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm 2009; 66: 1711-7
110. Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002; 5: 26-34 (Pubitemid 34160368)